CN104490840B - 泮托拉唑钠肠溶制剂及其制备方法 - Google Patents
泮托拉唑钠肠溶制剂及其制备方法 Download PDFInfo
- Publication number
- CN104490840B CN104490840B CN201410837154.6A CN201410837154A CN104490840B CN 104490840 B CN104490840 B CN 104490840B CN 201410837154 A CN201410837154 A CN 201410837154A CN 104490840 B CN104490840 B CN 104490840B
- Authority
- CN
- China
- Prior art keywords
- enteric
- pantoprazole sodium
- lubricant
- layer
- opacifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229960004048 pantoprazole sodium Drugs 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- 238000000576 coating method Methods 0.000 claims abstract description 92
- 239000010410 layer Substances 0.000 claims abstract description 74
- 239000011248 coating agent Substances 0.000 claims abstract description 66
- 239000000314 lubricant Substances 0.000 claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- 239000003381 stabilizer Substances 0.000 claims abstract description 38
- 239000012055 enteric layer Substances 0.000 claims abstract description 34
- 239000002904 solvent Substances 0.000 claims abstract description 34
- 239000003605 opacifier Substances 0.000 claims abstract description 32
- 239000011241 protective layer Substances 0.000 claims abstract description 27
- 238000000926 separation method Methods 0.000 claims abstract description 25
- 239000004014 plasticizer Substances 0.000 claims abstract description 16
- 239000002075 main ingredient Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 40
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical group [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 239000007884 disintegrant Substances 0.000 claims description 19
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 18
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 239000000945 filler Substances 0.000 claims description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- 239000000395 magnesium oxide Substances 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000004408 titanium dioxide Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 6
- 150000003851 azoles Chemical class 0.000 claims description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 240000000528 Ricinus communis Species 0.000 claims 1
- OPCRGEVPIBLWAY-QNRZBPGKSA-N ethyl (2E,4Z)-deca-2,4-dienoate Chemical compound CCCCC\C=C/C=C/C(=O)OCC OPCRGEVPIBLWAY-QNRZBPGKSA-N 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000010773 plant oil Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000428 dust Substances 0.000 abstract description 2
- 229940126409 proton pump inhibitor Drugs 0.000 abstract description 2
- 239000000612 proton pump inhibitor Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 20
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 17
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 17
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000008199 coating composition Substances 0.000 description 8
- 239000011122 softwood Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 241001269238 Data Species 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 3
- 239000000292 calcium oxide Substances 0.000 description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 229960003194 meglumine Drugs 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
主药成分 | 填充剂 | 稳定剂 | 崩解剂 | 粘合剂 | 润滑剂 |
泮托拉唑钠 | 甘露醇 | 氧化镁 | (低取代)羟丙纤维素 | 羟丙甲纤维素 | 硬脂酸镁 |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
1 | 白色 | 99.1% | 91.2% | 91.3% | 0.92% |
2 | 白色 | 101.2% | 93.1% | 96.2% | 0.71% |
3 | 白色 | 100.4% | 95.3% | 97.6% | 0.74% |
4 | 白色 | 98.3% | 90.2% | 94.3% | 0.97% |
5 | 白色 | 100.2% | 95.9% | 96.2% | 0.73% |
6 | 白色 | 100.3% | 94.3% | 98.6% | 0.74% |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
7 | 白色 | 99.8% | 91.5% | 98.4% | 0.82% |
8 | 白色 | 99.8% | 93.5% | 98.4% | 0.97% |
9 | 白色 | 99.8% | 94.5% | 98.4% | 0.74% |
10 | 白色 | 99.5% | 95.8% | 96.4% | 1.07% |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
11 | 与包衣层接触的片心层有浅黑色斑点 | 99.3% | 94.4% | 93.6% | 1.24% |
12 | 与包衣层接触的片心层有浅黑色斑点 | 99.2% | 96.4% | 94.3% | 1.27% |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
1 | 白色 | 99.3% | 95.8% | 98.1% | 1.15% |
2 | 白色 | 98.1% | 93.3% | 99.3% | 0.75% |
3 | 白色 | 101.3% | 94.1% | 98.7% | 0.77% |
4 | 白色 | 100.1% | 95.8% | 98.6% | 1.27% |
5 | 白色 | 100.5% | 97.5% | 98.4% | 0.76% |
6 | 白色 | 99.9% | 98.2% | 97.7% | 0.81% |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
7 | 与包衣层接近的片心变成浅黄色 | 97.1% | 92.1% | 91.7% | 1.21% |
8 | 与包衣层接近的片心变成微黄色 | 99.3% | 90.9% | 92.7% | 1.42% |
9 | 与包衣层接近的片心变成微黄色 | 99.1% | 92.1% | 94.2% | 1.17% |
10 | 与包衣层接近的片心变成微黄色 | 100.6% | 94.9% | 93.5% | 1.47% |
序号 | 片心性状 | 含量 | 释放度 | 耐酸力 | 有关物质 |
11 | 片心显灰黑色 | 98.1% | 96.2% | 96.7% | 1.81% |
12 | 片心显灰黑色 | 98.0% | 96.9% | 97.7% | 1.75% |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410837154.6A CN104490840B (zh) | 2013-12-30 | 2014-12-29 | 泮托拉唑钠肠溶制剂及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310747087 | 2013-12-30 | ||
CN2013107470874 | 2013-12-30 | ||
CN201410837154.6A CN104490840B (zh) | 2013-12-30 | 2014-12-29 | 泮托拉唑钠肠溶制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104490840A CN104490840A (zh) | 2015-04-08 |
CN104490840B true CN104490840B (zh) | 2018-09-28 |
Family
ID=52839403
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410834496.2A Active CN104523641B (zh) | 2013-12-30 | 2014-12-29 | 兰索拉唑肠溶制剂及其制备方法 |
CN201410836966.9A Pending CN104586772A (zh) | 2013-12-30 | 2014-12-29 | 质子泵抑制剂肠溶制剂及其包衣系统和制备方法 |
CN201410837154.6A Active CN104490840B (zh) | 2013-12-30 | 2014-12-29 | 泮托拉唑钠肠溶制剂及其制备方法 |
CN201410836476.9A Pending CN104546786A (zh) | 2013-12-30 | 2014-12-29 | 奥美拉唑肠溶制剂及其制备方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410834496.2A Active CN104523641B (zh) | 2013-12-30 | 2014-12-29 | 兰索拉唑肠溶制剂及其制备方法 |
CN201410836966.9A Pending CN104586772A (zh) | 2013-12-30 | 2014-12-29 | 质子泵抑制剂肠溶制剂及其包衣系统和制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410836476.9A Pending CN104546786A (zh) | 2013-12-30 | 2014-12-29 | 奥美拉唑肠溶制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN104523641B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825414B (zh) * | 2015-05-07 | 2018-11-16 | 山东新时代药业有限公司 | 一种稳定的s-泮托拉唑钠肠溶片 |
CN104887674B (zh) * | 2015-05-12 | 2019-07-23 | 上海信谊万象药业股份有限公司 | 一种含奥美拉唑的固体制剂及其制备方法 |
CN105534979A (zh) * | 2016-03-04 | 2016-05-04 | 中国药科大学 | 一种埃索美拉唑镁肠溶片剂及其制备方法 |
CN105833281B (zh) * | 2016-05-18 | 2018-02-02 | 连云港万泰医药辅料技术有限公司 | 一种水性肠溶薄膜包衣预混剂及其制备方法 |
CN106138000A (zh) * | 2016-07-19 | 2016-11-23 | 南京正宽医药科技有限公司 | 一种奥美拉唑肠溶片及其制备方法 |
CN107137372A (zh) * | 2017-05-07 | 2017-09-08 | 济南同路医药科技发展有限公司 | 奥美拉唑肠溶片及其制备方法 |
CN109125282B (zh) * | 2018-09-05 | 2020-07-14 | 珠海润都制药股份有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
CN110507628B (zh) * | 2019-09-30 | 2020-07-28 | 双鹤药业(海南)有限责任公司 | 一种雷贝拉唑钠素片、肠溶片及其制备方法 |
CN114569579B (zh) * | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
CN114617852B (zh) * | 2020-12-10 | 2023-06-27 | 昆药集团股份有限公司 | 一种奥美拉唑肠溶制剂及其制备方法 |
CN114191411B (zh) * | 2021-11-29 | 2023-02-28 | 苏州中化药品工业有限公司 | 一种质子泵抑制剂胶囊及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101378753A (zh) * | 2005-12-20 | 2009-03-04 | 特瓦制药工业有限公司 | 兰索拉唑口崩片 |
CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
CN102525990A (zh) * | 2010-12-23 | 2012-07-04 | 丽珠医药集团股份有限公司 | 一种艾普拉唑肠溶片剂及其制备¹法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US6306435B1 (en) * | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
CN101396348A (zh) * | 2008-10-25 | 2009-04-01 | 浙江华义医药有限公司 | 一种奥美拉唑肠溶微丸 |
CN102119927B (zh) * | 2010-01-11 | 2012-12-26 | 石药集团中奇制药技术(石家庄)有限公司 | 一种质子泵抑制剂的肠溶微丸制剂及其制备方法 |
CN102091084B (zh) * | 2010-12-09 | 2012-05-09 | 王勇 | 一种复方胶囊及其制备方法 |
CN103127026B (zh) * | 2013-02-05 | 2017-02-15 | 悦康药业集团有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
CN103340829B (zh) * | 2013-07-26 | 2015-04-08 | 珠海润都制药股份有限公司 | 一种质子泵抑制剂肠溶微丸 |
-
2014
- 2014-12-29 CN CN201410834496.2A patent/CN104523641B/zh active Active
- 2014-12-29 CN CN201410836966.9A patent/CN104586772A/zh active Pending
- 2014-12-29 CN CN201410837154.6A patent/CN104490840B/zh active Active
- 2014-12-29 CN CN201410836476.9A patent/CN104546786A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101378753A (zh) * | 2005-12-20 | 2009-03-04 | 特瓦制药工业有限公司 | 兰索拉唑口崩片 |
CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
CN102525990A (zh) * | 2010-12-23 | 2012-07-04 | 丽珠医药集团股份有限公司 | 一种艾普拉唑肠溶片剂及其制备¹法 |
Also Published As
Publication number | Publication date |
---|---|
CN104586772A (zh) | 2015-05-06 |
CN104523641A (zh) | 2015-04-22 |
CN104523641B (zh) | 2019-11-19 |
CN104490840A (zh) | 2015-04-08 |
CN104546786A (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104490840B (zh) | 泮托拉唑钠肠溶制剂及其制备方法 | |
CN104337789B (zh) | 雷贝拉唑钠肠溶制剂及其制备方法 | |
TWI744224B (zh) | 固形製劑 | |
BRPI0714915A2 (pt) | composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica | |
CA2785857A1 (en) | Production method of solid preparations and the solid preparations produced by the method | |
CN104958272B (zh) | 一种胃溶型薄膜包衣预混剂及其制备方法 | |
CN102970982B (zh) | 肠溶片剂 | |
CN108186593B (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN103126998A (zh) | 一种固态分散体和含有埃索美拉唑的药物组合物 | |
CN104382875B (zh) | 一种泮托拉唑钠肠溶片及其制备方法 | |
WO2017163170A1 (en) | Pharmaceutical composition comprising apixaban | |
CN104922086A (zh) | 一种质子泵抑制剂肠溶片的制备方法 | |
US20150157618A1 (en) | Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof | |
CN105640915A (zh) | 一种雷贝拉唑钠肠溶片及其制备工艺 | |
JP2019156857A (ja) | モンテルカストナトリウム製剤 | |
CN104188935B (zh) | 一种兰索拉唑肠溶片及其制备方法 | |
CN105343028B (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
RU2593771C2 (ru) | Энтеросолюбильная таблетка | |
CN108078944A (zh) | 含有替格瑞洛的固体组合物及其制备方法 | |
CN100423722C (zh) | 泮托拉唑或其盐的口服肠溶微丸及其制备工艺 | |
de Souza et al. | Film coating of nifedipine extended release pellets in a fluid bed coater with a Wurster insert | |
CN104337788B (zh) | 埃索美拉唑钠肠溶制剂及其制备方法 | |
US10258577B2 (en) | Multilayer solid pharmaceutical dosage forms | |
CN103565767B (zh) | 雷诺嗪缓释片片芯、包衣片及其制备方法 | |
JP2011201830A (ja) | フロセミド製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU DIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: DIKANG SCIENCE AND TECHNOLOGY PHARMACEUTICAL CO., LTD., SICHUAN PROV. Effective date: 20150505 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150505 Address after: 611731 Sichuan city of Chengdu province high tech Zone (West) No. 1 Dixon Road Applicant after: Chengdu Dikang Pharmaceutical Co., Ltd. Address before: 1 No. 611731 Sichuan city of Chengdu province high tech Zone Dikang Avenue Applicant before: Dikang Science and Technology Pharmaceutical Co., Ltd., Sichuan Prov. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 611731 Sichuan Chengdu high tech Zone (West District) di Kang Avenue No. 1 Applicant after: Chengdu Dikang pharmaceutical Limited by Share Ltd Address before: 611731 Sichuan Chengdu high tech Zone (West District) 1 Applicant before: Chengdu Dikang Pharmaceutical Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150408 Assignee: YAAN XUNKANG MEDICINE Co.,Ltd. Assignor: Chengdu Di Kang medicine companies LLC Contract record no.: X2021510000036 Denomination of invention: Pantoprazole sodium enteric coated preparation and its preparation method Granted publication date: 20180928 License type: Common License Record date: 20210915 |